How to buy Tyme Technologies stock (TYME)

Tyme Technologies is a biotechnology business based in the US. Tyme Technologies shares (TYME) are listed on the NASDAQ and all prices are listed in US Dollars. Tyme Technologies employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Tyme Technologies stock

Buy Tyme Technologies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Tyme Technologies stock price (NASDAQ: TYME)

Use our graph to track the performance of TYME stocks over time.

Tyme Technologies shares at a glance

• Key figures

Information last updated 2022-11-06.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.30
200-day moving average more info button	$0.36
Wall St. target price	$9.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.14

Is it a good time to buy Tyme Technologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tyme Technologies financials

Gross profit TTM	$0
Return on assets TTM	-15.71%
Return on equity TTM	-28.36%
Profit margin	0%
Book value	$0.43
Market Capitalization more info button	$53.5 million

TTM: trailing 12 months

Tyme Technologies share dividends

We're not expecting Tyme Technologies to pay a dividend over the next 12 months.

Have Tyme Technologies's shares ever split?

Tyme Technologies's shares were split on a 21654:4997 basis on 25 September 2014 . So if you had owned 4997 shares the day before before the split, the next day you'd have owned 21654 shares. This wouldn't directly have changed the overall worth of your Tyme Technologies shares – just the quantity. However, indirectly, the new 76.9% lower share price could have impacted the market appetite for Tyme Technologies shares which in turn could have impacted Tyme Technologies's share price.

Tyme Technologies share price volatility

Over the last 12 months, Tyme Technologies's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tyme Technologies's is 0.9189. This would suggest that Tyme Technologies's shares are less volatile than average (for this exchange).

Tyme Technologies overview

Tyme Technologies, Inc. , a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Frequently asked questions

What percentage of Tyme Technologies is owned by insiders or institutions?
Currently 30.764% of Tyme Technologies shares are held by insiders and 7.511% by institutions. How many people work for Tyme Technologies?
Latest data suggests 13 work at Tyme Technologies. When does the fiscal year end for Tyme Technologies?
Tyme Technologies's fiscal year ends in March. Where is Tyme Technologies based?
Tyme Technologies's address is: 1 Pluckemin Way, Bedminster, NJ, United States, 07921 What is Tyme Technologies's ISIN number?
Tyme Technologies's international securities identification number is: US90238J1034 What is Tyme Technologies's CUSIP number?
Tyme Technologies's Committee on Uniform Securities Identification Procedures number is: 90238J103